

# CHBG NEWSLETTER

## The Cochrane Hepato-Biliary Group (CHBG)

Volume 9, Issue 1

March 2005

*The numbering is a continuation from vol.8 issue 2, 2004*

### IN THIS ISSUE

#### CHBG REVIEWS AND PROTOCOLS IN THE CLIB ISSUE 1 AND 2, 2005

#### CHBG REVIEWS AND PROTOCOLS EXPECTED TO BE PUBLISHED IN THE CLIB ISSUE 3 AND 4, 2005

#### PAST EVENTS

- 18<sup>TH</sup> CHBG BI-ANNUAL MEETING DURING THE AASLD MEETING - BOSTON, USA
- THE 3<sup>RD</sup> ASIA PACIFIC EVIDENCE-BASED MEDICINE CONFERENCE - HONG KONG, CHINA

#### FUTURE EVENTS

- TRAIN THE TRAINERS
- THE 40<sup>TH</sup> ANNUAL EASL 2005 MEETING - PARIS, FRANCE
- THE 19<sup>TH</sup> CHBG MEETING AND EXHIBITION STAND
- 4<sup>TH</sup> BAVENO INTERNATIONAL CONSENSUS WORKSHOP AND 2<sup>ND</sup> POSTGRADUATE COURSE – BAVENO, ITALY
- DIGESTIVE DISEASE WEEK (DDW) - CHICAGO, USA
- THE 6<sup>TH</sup> PAN ARAB CONGRESS OF GASTROENTEROLOGY – BEIRUT, LEBANON

#### STAFF CHANGES

#### VISITS

#### COLLABORATION NEWS

- THE COCHRANE MANUAL
- IMPACT FACTOR FOR COCHRANE REVIEWS

#### PROGRAMME FOR 19<sup>TH</sup> CHBG MEETING

#### INVITATION FOR 19<sup>TH</sup> CHBG MEETING

### CHBG REVIEWS AND PROTOCOLS IN THE CLIB ISSUE 1 AND 2, 2005

#### NEW REVIEWS

43. Glucocorticosteroids for primary biliary cirrhosis. Prince M, Christensen E, and Gluud C.
44. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Rambaldi A, Jacobs BP, Iaquinto G, and Gluud C.

#### UPDATED REVIEWS

1. Somatostatin analogues for acute bleeding oesophageal varices. Gøtzsche PC and Hróbjartsson A.
2. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. Rambaldi A and Gluud C.

#### NEW PROTOCOLS

99. Acupuncture for chronic hepatitis B virus infection. Liu J and Wang J.
100. Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis. Orlando R, Orlando S, and Lirussi F.
101. Cyclosporin versus tacrolimus for liver transplanted patients. Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, and Gluud LL.
102. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Angelico F, Alessandri C, Burattin M, Del Ben M, Orlando S, and Lirussi F.
103. Elective surgery for benign liver tumours. Colli A, Fraquelli M, Massironi S, Colucci A, Paggi S, and Conte D.
104. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. Lirussi F, Mastropasqua E, Orlando S, and Orlando R.
105. Terlipressin for hepatorenal syndrome. Gluud LL, Kjaer MS, Taastroem A, and Christensen E.



106. Antibiotic prophylaxis for patients undergoing elective laparoscopic cholecystectomy. Sanabria A, Valdivieso E, and Gomez G.

107. Lamivudine for preventing reactivation of hepatitis B infection in patients planned to undergo immunosuppressive therapy. Katz LH, Fraser A, Leibovici L, and Tur-Kaspa R.

#### **UPDATED PROTOCOLS**

1. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Lirussi F, Orando S, Orlando R, and Angelico F.

#### **NEW REGISTERED TITLES**

196. Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome. Gluud LL.

197. Prostaglandins for liver transplanted patients. Cavalcante AB.

198. Percutaneous transhepatic biliary drainage for malignant obstructive jaundice. Wang C.

199. Screening interventions for early detection in patients with hepatocellular carcinoma. Dickinson J.

200. Early versus delayed laparoscopic cholecystectomy for acute cholecystitis. Gurusamy KS.

201. Prophylactic versus deferred cholecystectomy after endoscopic sphincterotomy to clear choledocholithiasis. McAlister, VC.

202. Chemotherapy for cholangiocarcinoma. Saeseow O.

203. Tiopronin for chronic hepatitis B. He Q.

204. Transmetil for chronic hepatitis B. He Q.

#### **CHBG REVIEWS AND PROTOCOLS TO BE PUBLISHED OR EXPECTED TO BE PUBLISHED IN THE CLIB ISSUE 3 AND 4, 2005**

##### **REVIEWS ACCEPTED FOR PUBLICATION AS OF TODAY**

- Bile acids for liver transplanted patients. Chen W and Gluud C.
- Portosystemic shunts versus endoscopic therapy for variceal rebleeding in patients with cirrhosis. Khan S, Tudur Smith C, Williamson P, and Sutton R.

##### **REVIEWS IN EDITORIAL PROCESS**

Presently 14 reviews are undergoing editorial evaluation.

- Antibiotics for cholangitis and/or cholecystitis. Kukuruzovic RH and Elliott EJ.

- D-penicillamine for primary sclerosing cholangitis. Frederiksen SL and Chen W.
- Methotrexate for primary biliary cirrhosis. Gong Y and Gluud C.
- Surgical versus endoscopic treatment of bile duct stones. Martin D, Vernon DR, Jobling J, and Toouli J.
- Vaccines for preventing hepatitis A. Tiberti D and Demicheli V.
- Bicyclol for chronic hepatitis B. Wu T, Hao B, and Liu G.
- Immunoglobulin for preventing hepatitis A. Liu JP, Yang M, and Du XM.
- Beta-interferon for chronic hepatitis B. Saconato H, Albuquerque ABM L, Gabriel FGS, and Atallah AN.
- Vitamin K for upper gastrointestinal bleeding in patients with liver diseases. Martí-Carvajal AJ and Martí-Peña AJ.
- Percutaneous needle aspiration with or without albendazole for uncomplicated hepatic hydatid cyst. Nasseri-Moghaddam S, Abrishami A, and Malekzadeh R.
- Vaccines for preventing hepatitis B in health-care workers. Chen W and Gluud C.
- Hepatitis B prophylaxis for newborns of hepatitis B surface antigen-positive mothers. Lee C, Gong Y, Brok J, Boxall EH, and Gluud C.
- Ribavirin monotherapy for chronic hepatitis C. Brok J, Gluud LL, and Gluud C.
- Bicyclol for chronic hepatitis B. Wu T, Hao B, and Liu G.

##### **UPDATES OF REVIEWS**

- Ribavirin plus interferon versus interferon for chronic hepatitis C by Brok J, Gluud C, and Gluud LL, is an update of a split review published with the title 'Ribavirin with or without alpha interferon for chronic hepatitis C'.

##### **REVIEWS IN NEED TO BE UPDATED IN THE CLIB ISSUE 3 OR 4, 2005**

- Neoadjuvant and adjuvant therapy for operable hepatocellular carcinoma. Chan ES-Y, Chow PK-H, Machin D, Soo K-C, and Samuel M.
- Emergency sclerotherapy versus medical interventions for bleeding oesophageal varices in cirrhotic patients. D'Amico G, Pagliaro LLP, Pietrosi GGPI, and Tarantino IITA.
- Interventions for paracetamol (acetaminophen) overdoses. Brok J, Buckley N, and Gluud C.



- Bile acids for primary sclerosing cholangitis. Chen W and Gluud C.
- Bile acids for viral hepatitis. Chen W, Liu J, and Gluud C.
- Sphincterotomy for biliary sphincter of Oddi dysfunction. Craig AG and Toouli J.
- Ursodeoxycholic acid for primary biliary cirrhosis. Gluud C and Christensen E.
- Antibiotics for preventing leptospirosis. Guidugli F, Castro AA, and Atallah AN.
- Antibiotics for leptospirosis. Guidugli F, Castro AA, and Atallah AN.
- Terlipressin for acute esophageal variceal hemorrhage. Ioannou G, Doust J, and Rockey DC.
- Chinese medicinal herbs for asymptomatic carriers of hepatitis B virus infection. Liu JP, McIntosh H, and Lin H.
- Chinese medicinal herbs for chronic hepatitis B. Liu JP, McIntosh H, and Lin H.
- Medicinal herbs for hepatitis C virus infection. Liu JP, Manheimer E, Tsutani K, and Gluud C.
- Sequential combination of glucocorticosteroids and alfa interferon versus alfa interferon alone for HBeAg-positive chronic hepatitis B. Mellerup MT, Krogsgaard K, Mathurin P, Gluud C, and Poynard T.
- Interferon for interferon naive patients with chronic hepatitis C. Myers RP, Regimbeau C, Thevenot T, Leroy V, Mathurin P, Opolon P, Zarski JP, and Poynard T.
- Interferon for acute hepatitis C. Myers RP, Regimbeau C, Thevenot T, Leroy V, Mathurin P, Opolon P, Zarski JP, and Poynard T.
- S-adenosyl-L-methionine for alcoholic liver diseases. Rambaldi A and Gluud C.
- Propylthiouracil for alcoholic liver disease. Rambaldi A and Gluud C.
- Anabolic-androgenic steroids for alcoholic liver disease. Rambaldi A, Iaquinto G, and Gluud C.
- Antibiotic prophylaxis for cirrhotic patients with gastrointestinal bleeding. Soares-Weiser K, Brezis M, Tur-Kaspa R, and Leibovici L.
- Antibiotics for spontaneous bacterial peritonitis in cirrhotics. Soares-Weiser K, Brezis M, and Leibovici L.
- Alpha-fetoprotein and/or liver ultrasonography for liver cancer screening in patients with chronic hepatitis B. Wun YT and Dickinson JA.

#### PROTOCOLS IN EDITORIAL PROCESS

Presently four protocols for reviews are undergoing editorial evaluation.

- Early versus delayed laparoscopic cholecystectomy for acute cholecystitis. Gurusamy KS and Samraj K.
- Antacids for preventing esophageal variceal bleeding and rebleeding in cirrhotic patients. Zhao P, Qiong W, and Yiping W.
- Pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis C. Simin M, Brok J, Stimac D, Gluud C, and Gluud LL.
- Preoperative biliary drainage for malignant obstructive jaundice. Wang C and Gurusamy KS.

---

#### PAST EVENTS

##### *18<sup>TH</sup> CHBG BI-ANNUAL MEETING DURING THE AASLD MEETING - BOSTON, USA*

The CHBG held its 18<sup>th</sup> meeting on 1 of November 2004. R. Koretz, E. Haddad, C Gluud and W Chen presented systematic reviews. The attendance was meager, but those present enjoyed the presentations.

##### *THE 3<sup>RD</sup> ASIA PACIFIC EVIDENCE-BASED MEDICINE CONFERENCE - HONG KONG, CHINA*

This conference was run from 26 to 28 of November 2004. Yan Gong, a Ph.D. student and a CHBG reviewer, presently working at The Editorial Team Office in Copenhagen, made an oral presentation: 'D-penicillamine for primary biliary cirrhosis: a systematic review of randomised clinical trials'.

---

#### FUTURE EVENTS

##### *TRAIN THE TRAINERS*

###### *In CAIRO, EGYPT*

A satellite Cairo Train the Trainers (TTT) Workshop will be run on 27 and 28 of March 2005. It is organised for the fifth time by Organisation Mondiale de Gastro-Entérologie (OMGE) and Organisation Mondiale D'Endoscopie Digestive (OMED) Education and Training Committee, under the elegant guidance of James Toouli, Australia. Christian Gluud is faculty member. On 29 of April there will be a hepatology session during a postgraduate course at which Christian Gluud will talk about evidence-based clinical practice for patients with liver disease.

###### *In PUNTA DEL ESTE, URUGUAY*



A TTT workshop will be run on 2 to 5 of April 2005. The workshop is organised by OMGE/OMED. Christian Gluud is faculty member on the workshop.

**THE 40<sup>TH</sup> ANNUAL EASL 2005 MEETING - PARIS, FRANCE**

It will be run from 13 to 17 of April 2005.

**THE 19<sup>TH</sup> CHBG MEETING AND EXHIBITION STAND**

The meeting will be held on 13 of April in Paris. Please see the programme on the last page of this Newsletter. We have spared the time from 11.00 am to 12:30 pm for people who would like to learn about preparation of Cochrane systematic reviews in general.

The CHBG is also given a stand at the EASL exhibition. Again this year the meeting and the stand are sponsored by EASL.

We will be happy to see as many of you as possible.

**4<sup>TH</sup> BAVENO INTERNATIONAL CONSENSUS WORKSHOP AND 2<sup>ND</sup> POSTGRADUATE COURSE – BAVENO, ITALY**

The symposium ‘Methodology of Diagnosis and Treatment in Portal Hypertension’ will be run from 27 to 29 April. For information please see: [http://www.falkfoundation.com/falk\\_symposia\\_workshops.html](http://www.falkfoundation.com/falk_symposia_workshops.html)

**DIGESTIVE DISEASE WEEK (DDW) - CHICAGO, USA**

The 106<sup>th</sup> DDW annual meeting will be run from 15 to 18 May 2005 in Chicago, USA. The Cochrane symposium, run this year by The Cochrane Colorectal Cancer Group with Editorial Team office in Copenhagen, Denmark, is scheduled Monday, 16 of May. Please feel free to participate. If you would like to receive the programme in advance, send an email to Henning Keinke Andersen, the coordinator of the group <HKA02@bbh.hosp.dk>.

**THE 6<sup>TH</sup> PAN ARAB CONGRESS OF GASTROENTEROLOGY – BEIRUT, LEBANON**

It will be run from 8 to 11 of June 2005. For more information, please visit <http://www.lsge.org/events/gastro2005>

---

**STAFF CHANGES**

Professor *Alberto Morabito*, Italy, resigned from his position of a statistical editor of The CHBG in

February 2005. He is thanked for his support to The CHBG during the years 1996 to 2005.

*Ninna Frydendall*, Denmark, stopped her working career at the age of 80 in February 2005. She had been working at the Editorial Team office of The CHBG on voluntary basis for more than six years. Her tasks within all these years varied, but maintaining the contact database and sending out The CHBG Newsletter to members was among her primary tasks. She has also contributed to the expansion of The CHBG Controlled Trials Register. She has downloaded references to studies of interest from electronic databases as well as entered citations manually. She was also the caring person finding accommodation to our guest researchers. She was the person who in the summer of 2002 showed Copenhagen area to a high-ranking delegation consisting of representatives from the Chinese Ministry of Health, The Chinese Cochrane Centre, and different provinces in China. She was the person assisting us at the EASL exhibitions. Her persevering nature will be long remembered. We wish her all the best, and we express our deep gratitude for all she has done for the CHBG members and us.

---

**VISITS**

*Andrea Rambaldi*, Italy, stayed for a week in December at the Editorial Team office and worked on an update of a systematic review, entitled ‘Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis’. He also finished the review ‘Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases’. Both reviews will be published in Issue 2, 2005.

*Marija Simin*, Croatia, came to Copenhagen on 28 of January 2005 and will stay in Copenhagen for four months in order to learn how to prepare Cochrane systematic reviews. The title she registered is ‘Pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis C’. By now she has written the protocol of the review and has continued with the review. Her stay is sponsored by the Department of Healthcare and Social Welfare in Croatia as well as by The Copenhagen Trial Unit, Denmark. She will present results of this review at The CHBG meeting in Paris.



---

---

## COLLABORATION NEWS

Due to the limited space we cannot inform our readers in details about new reports or policies of The Cochrane Collaboration or the working activities within entities. That is why we can only recommend that you visit regularly The Cochrane Collaboration website to follow the development <http://www.cochrane.org>

### THE COCHRANE MANUAL

The latest update of The Cochrane Manual (a 255-page document containing the policies and procedures of The Cochrane Collaboration) is now available on the Collaboration website

(<http://www.cochrane.org/admin/manual.htm>).

Due to the size of the document, it takes a little while to download.

Following is a list of the changes that have been made to the document since the previous version in November 2004:

- |                        |   |
|------------------------|---|
| <i>Section 1.5.8</i>   | Funding Arbiter (update)  |
| <i>Section 2.2.13</i>  | How to cite our products (update)   |
| <i>Section 2.2.6.1</i> | 'House rules' for responding to Comments and Criticisms on the web (update)                             |
| <i>Section 3.3.1</i>   | Guiding principles for Centre Directors and Staff (new)   |
| <i>Appendix 1</i>      | Co-publication agreements & correspondence with journal editors re publishing Cochrane Reviews (update) |
| <i>Appendix 2</i>      | Monitoring and Registration Group (update)  |
| <i>Appendix 3</i>      | Contact people at John Wiley and Sons (update).   |

By Ms Jini Hetherington

Administrator and Company Secretary

The Cochrane Collaboration Secretariat

## IMPACT FACTOR FOR COCHRANE REVIEWS

John Wiley & Sons, the publishers of The Cochrane Library, have agreed with the Institute for Scientific Information (ISI) that listing of Cochrane Reviews will lead to an impact factor for the Cochrane Database of Systematic Reviews (CDSR). An impact factor will be available mid 2007. When CDSR is accepted for listing, coverage for all Cochrane Reviews from Issue 1, 2004 onwards will be included.

Every article that ISI lists must be seen to have been published at a single point in time. Therefore, from Issue 2, 2004 the Wiley Interscience version of CDSR has retained the original online publication date for each review. The 'CD' Number of each review will act as a unique identifier for that review.

For the correct citation of the individual review please visit the Cochrane Library

(<http://www.thecochranelibrary.com>).

Please ensure that you cite reviews with the actual issue of publication rather than the currently available issue. If this is not done, the citation to the review will not be linked when counting the number of times that a review has been cited and calculating an impact factor for CDSR.

Labelling a review update as a substantive update will mean that it will be treated as a new article by ISC. The citations associated with the earlier review versions will not be linked to the record for the updated review and accumulation of citations will begin again.

The Cochrane Hepato-Biliary Group (CHBG) Newsletter is written, edited, and published in electronic and paper format by staff at the CHBG Editorial Base in Copenhagen, Denmark. It is issued twice a year and we distribute it for free world-wide to all people on The CHBG list who either have contributed, are contributing, or show interest in the work of The CHBG. The purpose is to inform CHBG members and other interested parties about activities within The CHBG.

Editorial CHBG staff at the CHBG Editorial Base: Christian Gluud, Co-ordinating & Criticism Editor, E-mail: <[cgluud@ctu.rh.dk](mailto:cgluud@ctu.rh.dk)>; Dimitrinka Nikolova, Review Group Co-ordinator, E-mail: <[dnikolov@ctu.rh.dk](mailto:dnikolov@ctu.rh.dk)>; Sarah Louise Klingenberg, Trials Search Co-ordinator, E-mail: <[slk@ctu.rh.dk](mailto:slk@ctu.rh.dk)>; Nader Salas, IT advisor, E-mail: <[nader.s@ctu.rh.dk](mailto:nader.s@ctu.rh.dk)>; Styrbjørn Birch, IT help and WEB master, E-mail: <[s.birch@ctu.rh.dk](mailto:s.birch@ctu.rh.dk)>


Cochrane Hepato-Biliary Group, Copenhagen Trial Unit,  
Dept. 7102, H:S Rigshospitalet, Blegdamsvej 9, DK-2100  
Copenhagen Ø, Denmark,

Tel. +45 3545 7169 or +3545 7175, Fax +45 3545 7101,

E-mail: <[dnikolov@ctu.rh.dk](mailto:dnikolov@ctu.rh.dk)>

Website: <<http://inet.uni2.dk/~ctucph/chbg>>





**PROGRAMME**  
**FOR THE 19<sup>th</sup> COCHRANE HEPATO-BILIARY GROUP (CHBG)**  
**BI-ANNUAL MEETING,**  
**DURING THE 2005 EASL MEETING, PARIS - FRANCE**

**Date: 13 April 2005**

**Time: 11:00 to 14:00**

**Place: Hall 252A**

**Venue: Palais de Congres,  
2, Place de la Porte Maillot,  
Paris 75017, France**

---

11:00 – 12:30	Introduction to Cochrane systematic reviews.	<u>Nikolova D</u> (DK), Brok J (DK), Gluud C (DK), Gluud LL (DK), Gong Y (DK), Klingenberg S (DK).
---------------	--	--

---

Chair: Christian Gluud

---

12:30 – 12:40	Welcome and presentation of the programme. The CHBG in its ninth year.	<u>Gluud C</u> (DK).
12:40 – 13:00	Terlipressin for hepatorenal syndrome. A Cochrane Review.	<u>Gluud LL</u> (DK), Kjaer MS (DK), Taastrom A (DK), Christensen E (DK).
13:00 - 13:20	Ribavirin plus interferon versus interferon for chronic hepatitis C. A Cochrane Review.	<u>Brok J</u> (DK), Gluud LL (DK), Gluud C (DK).
13:20 - 13:40	Pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis C. A Cochrane Review.	<u>Simin M</u> (HR), Brok J (DK), Stimac D (HR), Gluud C (DK), Gluud LL (DK).
13:40 –14:00	D-penicillamine for primary biliary cirrhosis. A Cochrane Review.	<u>Gong Y</u> (DK), Klingenberg SL (DK), Gluud C (DK).

Discussions and closing of the meeting.

---

